PDF herunterladen
Semin intervent Radiol 2016; 33(03): 244-250
DOI: 10.1055/s-0036-1586148
Clinical Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Benign Prostatic Hyperplasia: Review of Modern Minimally Invasive Surgical Treatments

Tony Nimeh
1   Department of Urology, University of Illinois at Chicago, Chicago, Illinois
,
Brenden Magnan
1   Department of Urology, University of Illinois at Chicago, Chicago, Illinois
,
Y. Zaki Almallah
1   Department of Urology, University of Illinois at Chicago, Chicago, Illinois
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. August 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Benign prostatic hyperplasia (BPH) is a common problem among older men and can have a significant impact on quality of life. BPH is a histologically diagnosed disease and is present in 8% of men aged 41 to 50, 40 to 50% of men aged 51 to 60, 70% of men aged 61 to 70, and more than 80% of men older than 80 years. The pathogenesis of BPH remains incompletely understood, but there are many known risk factors for developing this disease. These include race, family history of cancer, higher serum levels of testosterone and estradiol, alcohol consumption, prostatitis, and nonsteroidal anti-inflammatory drug use.[1] [2] [3] [4] [5] The classic clinical presentation of BPH is the experience of lower urinary tract symptoms (LUTS). These symptoms include frequency, nocturia, urgency, incontinence, slow or intermittent stream, straining, and terminal dribbling ([Table 1]). These symptoms are experienced moderately to severely in 25% of men in their 50s, 33% of men in their 60s, and approximately 50% of men in their 80s. Like any other disease, the clinical evaluation for a man with suspected BPH begins with a thorough history and physical exam. The International Prostate Symptom Score (IPSS) index can be used to classify the severity of LUTS in patients. This consists of seven questions that assess the severity and frequency of different symptoms of BPH as well as a question asking the patient to rate how their quality of life is affected by these symptoms.[6]

Table 1

BPH Symptoms[7]

Storage symptoms

Voiding symptoms

Increased frequency

Nocturia

Urgency

Feeling of incomplete emptying

Intermittency

Straining

Weak stream

Abbreviation: BPH, benign prostatic hyperplasia.


 

  • References

  • 1 Negri E, Pelucchi C, Talamini R , et al. Family history of cancer and the risk of prostate cancer and benign prostatic hyperplasia. Int J Cancer 2005; 114 (4) 648-652
    CrossrefPubMedGoogle Scholar
  • 2 Kristal AR, Schenk JM, Song Y , et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2008; 168 (12) 1416-1424
    CrossrefPubMedGoogle Scholar
  • 3 Crispo A, Talamini R, Gallus S , et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. Urology 2004; 64 (4) 717-722
    CrossrefPubMedGoogle Scholar
  • 4 St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Lieber MM, Jacobsen SJ. Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology 2008; 71 (3) 475-479 , discussion 479
    CrossrefPubMedGoogle Scholar
  • 5 St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006; 164 (8) 760-768
    CrossrefPubMedGoogle Scholar
  • 6 McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12 (5, Suppl): S122-S128
    PubMedGoogle Scholar
  • 7 American Urological Association Guideline Management of Benign Prostatic Hyperplasia (BPH): American Urological Association Education and Research, Inc., 2010
  • 8 Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials. Eur Urol 2009; 56 (5) 798-809
    CrossrefPubMedGoogle Scholar
  • 9 Lee SW, Choi JB, Lee KS , et al. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: a quality and meta-analysis. Int Neurourol J 2013; 17 (2) 59-66
    CrossrefPubMedGoogle Scholar
  • 10 Te AE. The next generation in laser treatments and the role of the green light high-performance system laser. Rev Urol 2006; 8 (Suppl. 03) S24-S30
    PubMedGoogle Scholar
  • 11 Te AE, Malloy TR, Stein BS , et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 2004; 172 (4, Pt 1) 1404-1408
    CrossrefPubMedGoogle Scholar
  • 12 Ruszat R, Wyler S, Forster T , et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007; 51 (4) 1031-1038 , discussion 1038–1041
    CrossrefPubMedGoogle Scholar
  • 13 Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol 2012; 62 (2) 315-323
    CrossrefPubMedGoogle Scholar
  • 14 Suardi N, Gallina A, Salonia A , et al. Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. Curr Opin Urol 2009; 19 (1) 38-43
    CrossrefPubMedGoogle Scholar
  • 15 Elterman DS, Chughtai B, Lee R , et al. Comparison of techniques for transurethral laser prostatectomy: standard photoselective vaporization of the prostate versus transurethral laser enucleation of the prostate. J Endourol 2013; 27 (6) 751-755
    CrossrefPubMedGoogle Scholar
  • 16 Kumar SM. Rapid communication: holmium laser ablation of large prostate glands: an endourologic alternative to open prostatectomy. J Endourol 2007; 21 (6) 659-662
    CrossrefPubMedGoogle Scholar
  • 17 Mottet N, Anidjar M, Bourdon O , et al. Randomized comparison of transurethral electroresection and holmium: YAG laser vaporization for symptomatic benign prostatic hyperplasia. J Endourol 1999; 13 (2) 127-130
    CrossrefPubMedGoogle Scholar
  • 18 Seki N, Naito S. Holmium laser for benign prostatic hyperplasia. Curr Opin Urol 2008; 18 (1) 41-45
    CrossrefPubMedGoogle Scholar
  • 19 Elzayat EA, Al-Mandil MS, Khalaf I, Elhilali MM. Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. J Urol 2009; 182 (1) 133-138
    CrossrefPubMedGoogle Scholar
  • 20 Elmansy HM, Elzayat E, Elhilali MM. Holmium laser ablation versus photoselective vaporization of prostate less than 60 cc: long-term results of a randomized trial. J Urol 2010; 184 (5) 2023-2028
    CrossrefPubMedGoogle Scholar
  • 21 Tan A, Liao C, Mo Z, Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 2007; 94 (10) 1201-1208
    CrossrefPubMedGoogle Scholar
  • 22 Ahyai SA, Gilling P, Kaplan SA , et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58 (3) 384-397
    CrossrefPubMedGoogle Scholar
  • 23 Lourenco T, Pickard R, Vale L , et al; Benign Prostatic Enlargement team. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ 2008; 337: a449
    CrossrefPubMedGoogle Scholar
  • 24 Geavlete B, Multescu R, Dragutescu M, Jecu M, Georgescu D, Geavlete P. Transurethral resection (TUR) in saline plasma vaporization of the prostate vs standard TUR of the prostate: ‘the better choice’ in benign prostatic hyperplasia?. BJU Int 2010; 106 (11) 1695-1699
    CrossrefPubMedGoogle Scholar
  • 25 Geavlete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP-A prospective, randomized, long-term comparison. Urology 2011; 78 (4) 930-935
    CrossrefPubMedGoogle Scholar
  • 26 Karaman MI, Kaya C, Ozturk M, Gurdal M, Kirecci S, Pirincci N. Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. J Endourol 2005; 19 (6) 734-737
    CrossrefPubMedGoogle Scholar
  • 27 Hoffman RM, Monga M, Elliott SP , et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012; 9: CD004135
    PubMedGoogle Scholar
  • 28 Djavan B, Kazzazi A, Bostanci Y. Revival of thermotherapy for benign prostatic hyperplasia. Curr Opin Urol 2012; 22 (1) 16-21
    CrossrefPubMedGoogle Scholar
  • 29 Mynderse LA, Roehrborn CG, Partin AW, Preminger GM, Coté EP. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 2011; 185 (5) 1804-1810
    CrossrefPubMedGoogle Scholar
  • 30 Tan AH, Nott L, Hardie WR, Chin JL, Denstedt JD, Razvi H. Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 2005; 19 (10) 1191-1195
    CrossrefPubMedGoogle Scholar
  • 31 Vesely S, Knutson T, Damber JE, Dicuio M, Dahlstrand C. TURP and low-energy TUMT treatment in men with LUTS suggestive of bladder outlet obstruction selected by means of pressure-flow studies: 8-year follow-up. Neurourol Urodyn 2006; 25 (7) 770-775
    CrossrefPubMedGoogle Scholar
  • 32 Hill B, Belville W, Bruskewitz R , et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171 (6, Pt 1) 2336-2340
    CrossrefPubMedGoogle Scholar
  • 33 Boyle P, Robertson C, Vaughan ED, Fitzpatrick JM. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int 2004; 94 (1) 83-88
    CrossrefPubMedGoogle Scholar
  • 34 Chin PT, Bolton DM, Jack G , et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012; 79 (1) 5-11
    CrossrefPubMedGoogle Scholar
  • 35 Armitage JN, Cathcart PJ, Rashidian A, De Nigris E, Emberton M, van der Meulen JH. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. J Urol 2007; 177 (5) 1619-1624
    CrossrefPubMedGoogle Scholar
  • 36 Bilhim T, Pisco J, Campos Pinheiro L , et al. Does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study. J Vasc Interv Radiol 2013; 24 (11) 1595-602.e1
    CrossrefPubMedGoogle Scholar
  • 37 A Pereira J, Bilhim T, Duarte M, Rio Tinto H, Fernandes L, Martins Pisco J. Patient selection and counseling before prostatic arterial embolization. Tech Vasc Interv Radiol 2012; 15 (4) 270-275
    CrossrefPubMedGoogle Scholar
  • 38 Carnevale FC, Antunes AA. Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it. Cardiovasc Intervent Radiol 2013; 36 (6) 1452-1463
    CrossrefPubMedGoogle Scholar
  • 39 Antunes AA, Carnevale FC, da Motta Leal Filho JM , et al. Clinical, laboratorial, and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia. A prospective single-center pilot study. Cardiovasc Intervent Radiol 2013; 36 (4) 978-986
    CrossrefPubMedGoogle Scholar
  • 40 Ditrolio J, Patel P, Watson RA, Irwin RJ. Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002; 167 (5) 2100-2103 , discussion 2103–2104
    CrossrefPubMedGoogle Scholar
  • 41 Plante MK, Bunnell ML, Trotter SJ, Jackson TL, Esenler AC, Zvara P. Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radio-frequency energy and ethanol. Prostate Cancer Prostatic Dis 2002; 5 (3) 183-188
    CrossrefPubMedGoogle Scholar
  • 42 Bschleipfer T, Bach T, Gratzke C, Madersbacher S, Oelke M. [Intraprostatic injection therapy in patients with benign prostatic syndrome]. Urologe A 2013; 52 (3) 354-358
    CrossrefPubMedGoogle Scholar
  • 43 Sacco E, Bientinesi R, Marangi F , et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int 2012; 110 (11, Pt C): E837-E844
    CrossrefPubMedGoogle Scholar